Type 2 diabetes
Conditions
Interventions
After taking metformin or vildagliptin for 12 weeks, PET/MRI is taken
Blood tests are performed monthly and feces are collected before and after treatment
Sponsors
Kobe university
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Type 2 diabetes 2.20-75 years old 3.Patients who are judged by the attending physician to be required to receive metformin or vildagliptin 4.Patients who showed an understanding of the medication method in this study 5.Patients who have obtained written consent from the person 6.Patients who have only diet/exercise therapy for diabetes treatment within the last month
Exclusion criteria
Exclusion criteria: 1.Patients who are pregnant or breastfeeding and may become pregnant 2.Patients with a history of skin lesions with oral hypoglycemic agents or insulin 3.Patients with type 1 diabetes, including slowly progressive type, or other types of diabetes 4.Severe liver dysfunction 5.Severe renal dysfunction 6.Patients with severe cardiac dysfunction 7.Users of alpha glucosidase inhibitors, DPP4 inhibitors, SGLT2 inhibitors, and GLP1 receptor agonists within 1 month 8.Patients who have used antibiotics or antiparasitics within 1 month 9.Patients who used laxatives within 1 month 10.Patients who took PPI, corticosteroids, and immunosuppressive drugs within 1 month 11.Gastrointestinal diseases 12.Patients who have had gastrointestinal surgery in the past 13.Patients with new or recurrent malignancies within 1 year 14.Patients who are judged by the attending physician to have a mental illness 15.Patients who have internal implants 16.Others who are judged by researchers to be unsuitable for this research 17.Patients who are judged by the attending physician to be in acute metabolic ataxia 18.Patients who are judged to be unsuitable for taking the study drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Comparison of semi-quantitative evaluation (SUVmean) of FDG accumulation at each site of the intestinal tract in the metformin group and vildagliptin group analyzed using 18F-FDG-PET/MRI 12 weeks after the start of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in glycemic control, weight, and abdominal circumference before and after treatment | — |
Countries
Japan
Contacts
Public ContactKazuhiko Sakaguchi
Kobe university Department of Diabetes and Endocrinology
Outcome results
None listed